For PSP, they are AADvac1, AZP2006, and a drug to be announced. For CBS, no official word, but the drug is likely BIIB080. Industry representatives from 52 companies joined. “That was great to see,” ...

supported by factors such as the expected approval of new treatments and diagnostics for Alzheimer’s disease and promising pipeline developments like BIIB080 and Litifilimab.

The company received FDA Fast Track designation for its ASO targeting BIIB080, indicating confidence in its potential for Alzheimer's treatment. LEQEMBI received marketing authorization in the EU ...

The company received FDA Fast Track designation for its ASO targeting BIIB080, indicating confidence in its potential for Alzheimer's treatment. LEQEMBI received marketing authorization in the EU, ...

Pipeline advancements included FDA Fast Track designation for BIIB080 in Alzheimer’s and initiation of the TRANSCEND study for felzartamab in AMR. Management tone showed increased confidence in ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

And there we're very happy to get the FDA Fast Track designation for our ASO targeting BIIB080. That's remarkable since that we haven't actually even read out Phase 2 yet. And I think it's a sign ...

supported by factors such as the expected approval of new treatments and diagnostics for Alzheimer’s disease and promising pipeline developments like BIIB080 and Litifilimab. Overall ...

A randomized, double-blind, placebo-controlled, multiple-ascending dose (MAD) Phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and target engagement of the tau-targeting antisense ...